KOSDAQ-listed bio firm to go under review for unfaithful disclosure
--------------------------------------------------------------------
Source: South Korea
Published: 2026-04-16 12:47 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Culture & Entertainment, Asia, South Korea, Drugs, Asia Pacific
--------------------------------------------------------------------
Snippet:
SEOUL, April 16 (Yonhap) -- South Korea's main bourse operator said Thursday it is set to review a bio firm, whose stocks rallied recently amid hype over its weight-loss drugs and oral insulin, to determine whether the firm violated disclosure regulations.
--------------------------------------------------------------------